# Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

> **NCT00611351** · PHASE2 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 5 (actual)

## Conditions studied

- Graft Versus Host Disease
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Diseases
- Secondary Myelofibrosis

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **DRUG:** busulfan
- **DRUG:** cyclophosphamide
- **DRUG:** mycophenolate mofetil
- **DRUG:** tacrolimus
- **GENETIC:** polymerase chain reaction
- **GENETIC:** polymorphism analysis
- **OTHER:** flow cytometry
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacogenomic studies
- **OTHER:** pharmacological study
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00611351
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06-07
- **Primary completion:** 2008-02-01
- **Final completion:** 2008-09-17
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2023-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00611351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00611351, "Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00611351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*